IL321704A - Human serum albumin in formulations - Google Patents

Human serum albumin in formulations

Info

Publication number
IL321704A
IL321704A IL321704A IL32170425A IL321704A IL 321704 A IL321704 A IL 321704A IL 321704 A IL321704 A IL 321704A IL 32170425 A IL32170425 A IL 32170425A IL 321704 A IL321704 A IL 321704A
Authority
IL
Israel
Prior art keywords
formulation
fatty acid
polysorbate
serum albumin
human serum
Prior art date
Application number
IL321704A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL321704A publication Critical patent/IL321704A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
IL321704A 2019-03-05 2020-03-03 Human serum albumin in formulations IL321704A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813843P 2019-03-05 2019-03-05
PCT/US2020/020752 WO2020180850A1 (en) 2019-03-05 2020-03-03 Human serum albumin in formulations

Publications (1)

Publication Number Publication Date
IL321704A true IL321704A (en) 2025-08-01

Family

ID=70190088

Family Applications (2)

Application Number Title Priority Date Filing Date
IL321704A IL321704A (en) 2019-03-05 2020-03-03 Human serum albumin in formulations
IL285938A IL285938B2 (en) 2019-03-05 2020-03-03 Human serum albumin in formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL285938A IL285938B2 (en) 2019-03-05 2020-03-03 Human serum albumin in formulations

Country Status (13)

Country Link
US (2) US11241499B2 (https=)
EP (1) EP3934620A1 (https=)
JP (2) JP7561748B2 (https=)
CN (1) CN113543811A (https=)
AU (2) AU2020232683B2 (https=)
BR (1) BR112021015790A2 (https=)
CA (1) CA3130457A1 (https=)
EA (1) EA202192422A1 (https=)
IL (2) IL321704A (https=)
MX (1) MX2021010558A (https=)
SG (1) SG11202109004TA (https=)
WO (1) WO2020180850A1 (https=)
ZA (1) ZA202106012B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
CN116457020A (zh) * 2020-11-16 2023-07-18 W.L.戈尔及同仁股份有限公司 不含脂肪酸颗粒的制剂、方法和预填充注射装置
KR20240021921A (ko) * 2021-06-14 2024-02-19 리제너론 파아마슈티컬스, 인크. 초고감도 비추출 지방산 정량화 방법을 사용한 제약 제형 중 폴리소르베이트 가수분해 모니터링

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937188A (en) 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US5190864A (en) 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US4801726A (en) 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US5412083A (en) 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
JPH0733398B2 (ja) * 1992-07-31 1995-04-12 株式会社ミドリ十字 ヒト血清アルブミンの脱脂方法
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO1996025425A1 (en) 1995-02-16 1996-08-22 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6441160B2 (en) 1998-05-11 2002-08-27 Tosoh Corporation Separating plasmids from contaminants using hydrophobic or hydrophobic and ion exchange chromatography
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US7101982B2 (en) 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
JP2006507249A (ja) 2002-09-13 2006-03-02 バイオジェン アイデック インコーポレイテッド 疑似移動床式クロマトグラフィーによる、ポリペプチドを精製する方法
JPWO2004087761A1 (ja) 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
KR101150050B1 (ko) 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
WO2006020622A1 (en) 2004-08-09 2006-02-23 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US7795405B2 (en) 2004-08-09 2010-09-14 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2583578C (en) 2004-10-21 2014-04-01 Ge Healthcare Bio-Sciences Ab Chromatography ligand
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
US20080299671A1 (en) 2005-12-02 2008-12-04 Ge Healthcare Bio-Sciences Ab Hydrophobic Interaction Chromatography
JP2009531371A (ja) 2006-03-28 2009-09-03 エフ.ホフマン−ラ ロシュ アーゲー 抗igf−1rヒト・モノクローナル抗体製剤
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US9766217B2 (en) 2006-09-08 2017-09-19 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
US20080299545A1 (en) 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
EP2252952B1 (en) 2008-01-25 2019-03-13 Biogen MA Inc. Automated system and method for monitoring chromatography column performance, and applications thereof
US8410928B2 (en) 2008-08-15 2013-04-02 Biogen Idec Ma Inc. Systems and methods for evaluating chromatography column performance
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
KR20180000341A (ko) 2009-06-16 2018-01-02 젠자임 코포레이션 재조합 aav 벡터에 대한 개선된 정제 방법
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
US8246833B2 (en) 2009-12-17 2012-08-21 Ge Healthcare Bio-Sciences Ab Chromatography column and maintenance method
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CN102762585B (zh) 2010-02-12 2016-01-20 DPx控股有限公司 单一单元抗体纯化
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CA2792517C (en) 2010-03-09 2020-03-24 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
CN103443628A (zh) 2011-03-28 2013-12-11 积水医疗株式会社 Psa测定方法及其试剂
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
JP6092892B2 (ja) 2011-12-15 2017-03-08 プレステージ バイオファーマ プライベート リミテッド 抗体の精製方法
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
TW201348247A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質a親和性層析之非人類抗體之新穎純化
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2895198A1 (en) 2012-12-20 2014-06-26 Medimmune, Llc Liquid antibody formulation with improved aggregation properties
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
BR112015017307A2 (pt) 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI670279B (zh) 2013-03-15 2019-09-01 Alder Biopharmaceuticals, Inc. 抗體純化及純度監測
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
US9150938B2 (en) 2013-06-12 2015-10-06 Orochem Technologies, Inc. Tagatose production from deproteinized whey and purification by continuous chromatography
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
US20150093800A1 (en) 2013-09-05 2015-04-02 Genentech, Inc. Method for chromatography reuse
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20160251441A1 (en) 2013-10-25 2016-09-01 Medimmune, Llc Antibody purification
US10115576B2 (en) 2013-12-12 2018-10-30 Waters Technologies Corporation Method and an apparatus for analyzing a complex sample
WO2015095568A1 (en) * 2013-12-18 2015-06-25 Kelvin Lee Reduction of lipase activity in product formulations
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
AR102198A1 (es) * 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2016089886A2 (en) 2014-12-02 2016-06-09 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an il-6r antagonist
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
AU2016378573A1 (en) 2015-12-22 2018-07-19 Regeneron Pharmaceuticals, Inc. Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN115400220A (zh) * 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
BR112018075667B1 (pt) 2016-06-14 2024-02-20 Biogen Ma, Inc Métodos para separar um oligonucleotídeo alvo de uma mistura contendo o oligonucleotídeo alvo e uma impureza relacionada com o produto
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗muc16(ムチン16)抗体
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
MA49962A (fr) 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
JP7462566B2 (ja) 2018-03-16 2024-04-05 ブリストル-マイヤーズ スクイブ カンパニー タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
WO2019178495A1 (en) 2018-03-16 2019-09-19 Biogen Ma Inc. Methods for purifying recombinant adeno-associated viruses
EP3774882A1 (en) 2018-03-29 2021-02-17 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
US20210122783A1 (en) 2018-06-19 2021-04-29 Bristol-Myers Squibb Company Methods of purifying proteins using chromatography
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3826743A4 (en) 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. METHODS FOR SEPARATION OF HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC METHODS
KR20210045425A (ko) 2018-08-15 2021-04-26 브리스톨-마이어스 스큅 컴퍼니 하류 크로마토그래피에서의 재산화에 의한 단백질 단편화 제어 전략
EP3876996A1 (en) 2018-11-05 2021-09-15 Bristol-Myers Squibb Company Method for purifying pegylated protein
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
US12174161B2 (en) 2019-03-29 2024-12-24 Bristol-Myers Squibb Company Methods of measuring hydrophobicity of chromatographic resins
CN114173827B (zh) 2019-06-28 2025-01-28 武田药品工业株式会社 腺相关病毒纯化方法

Also Published As

Publication number Publication date
JP2024178351A (ja) 2024-12-24
AU2025283473A1 (en) 2026-01-15
CA3130457A1 (en) 2020-09-10
IL285938B2 (en) 2025-11-01
AU2020232683B2 (en) 2025-10-02
US11241499B2 (en) 2022-02-08
US20200282063A1 (en) 2020-09-10
WO2020180850A1 (en) 2020-09-10
IL285938B1 (en) 2025-07-01
CN113543811A (zh) 2021-10-22
JP2022523962A (ja) 2022-04-27
JP7561748B2 (ja) 2024-10-04
US20220118097A1 (en) 2022-04-21
IL285938A (en) 2021-10-31
SG11202109004TA (en) 2021-09-29
MX2021010558A (es) 2021-10-13
US12594337B2 (en) 2026-04-07
ZA202106012B (en) 2025-04-30
EA202192422A1 (ru) 2021-12-09
EP3934620A1 (en) 2022-01-12
KR20210135543A (ko) 2021-11-15
BR112021015790A2 (pt) 2021-10-05
AU2020232683A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
IL321704A (en) Human serum albumin in formulations
Heid et al. Intracellular origin and secretion of milk fat globules
Vudhichamnong et al. The effect of secretory immunoglobulin A on the in-vitro adherence of the yeast Candida albicans to human oral epithelial cells
EP0713700B1 (en) Use of lauric acid or a monoglyceride of a C8-C16 fatty acid for inhibiting Helicobacter
LU93314I2 (https=)
DE69532088D1 (de) Verfahren zur steigerung der immunogenizität, erhaltenes produkt und arzneimittel
MY162623A (en) Immunoglobulin formulation and method of preparation thereof
KR20190125318A (ko) 항-rsv 모노클로날 항체 제제
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
ATE55243T1 (de) Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung.
Jones et al. Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
McLean et al. P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission
JP2022523962A5 (https=)
Ge et al. Relationship of tissue and cellular interleukin-1 and lipopolysaccharide after endotoxemia and bacteremia
Larsen et al. The adjuvant effect of di-(2-ethylhexyl) phthalate is mediated through a PPARα-independent mechanism
Chandra Nutritional regulation of immunity and infection: from epidemiology to phenomenology to clinical practice
Takano et al. Differential distribution of salivary agglutinin and amylase in the Golgi apparatus and secretory granules of human salivary gland acinar cells
Vervelde et al. Induction of a local and systemic immune response using cholera toxin as vehicle to deliver antigen in the lamina propria of the chicken intestine
Cocco Martin et al. Characterization of antibody labelled colloidal gold particles and their applicability in a sol particle immuno assay (SPIA)
Hohlfeld et al. Expression of 65‐kd heat shock proteins in the inflammatory myopathies
Wilkhu et al. Consideration of the efficacy of non-ionic vesicles in the targeted delivery of oral vaccines
Youssry et al. Association of hepatitis B vaccine response to vitamin D supplementation and ultraviolet B (UVB) exposure during different time intervals in experimental animals
JP2022538263A (ja) マイコトキシン症に対する防御のためのコンジュゲート化デオキシニバレノール
Rahman et al. Influence of maternal gestational treatment with mycobacterial antigens on postnatal immunity in an experimental murine model